Bristol Myers Squibb — how they publish

10 posts · curated by ViralLoop

80 posts from @bmsnews, Jan 2025 to Aug 2026: a typical post earns 14 likes and 2 replies. That is more than 70% of the 275 other S&P 500 companies we hold content for. About 1 in 4 of their posts opens with a number.

Bristol Myers Squibb@bmsnews

Today, we announced a global strategic partnership with @BioNTech_Group to co-develop and co-commercialize BNT327, an investigational, next-generation PD-L1/VEGF bispecific antibody, across numerous solid tumor types. Learn more: t.co

Opens with an announcement

Bristol Myers Squibb@bmsnews

#MEDIA: Announcing the final analysis of OS from the CheckMate -816 trial evaluating our #immunotherapy used in combination with chemotherapy regimen as neoadjuvant treatment of resectable non-small cell #lungcancer. #NSCLC #LCSM t.co

Opens with an observation

Bristol Myers Squibb@bmsnews

#MEDIA: Today, we announced a $2.3 billion investment to build a new manufacturing campus in Houston, Texas. Read more: t.co

Opens with a number

Bristol Myers Squibb@bmsnews

#MEDIA Announcing our first-of-its-kind RayzeBio site in Indianapolis, a cutting-edge U.S. manufacturing facility advancing our mission to deliver innovative medicines to patients.

Opens with an observation

Bristol Myers Squibb@bmsnews

#MEDIA: The U.S. FDA approved an update to the required echo monitoring for our first-in-class treatment for adults living with symptomatic obstructive #HypertrophicCardiomyopathy: t.co

Opens with an observation

Bristol Myers Squibb@bmsnews

#MEDIA: @US_FDA granted accelerated approval to our new CELMoD treatment for relapsed or refractory #MultipleMyeloma in adults, introducing a new class of treatment. t.co

Opens with an observation

Bristol Myers Squibb@bmsnews

MEDIA: The @US_FDA has granted Breakthrough Therapy Designation to our investigational EGFRxHER3 bispecific ADC for previously treated EGFR-mutant NSCLC. Read More: t.co

Opens with an observation

Bristol Myers Squibb@bmsnews

#MEDIA: @US_FDA has approved the removal of REMS and streamlined patient monitoring requirements for our #CARTcelltherapies, a landmark update that will help foster increased patient access for this important treatment modality. t.co

Opens with an observation

Bristol Myers Squibb@bmsnews

#MEDIA: Announcing the @US_FDA has granted priority review of the application for our #immunotherapy-based combination for adult and pediatric patients with previously untreated Stage III or IV Classical #HodgkinLymphoma. t.co

Opens with an observation

Bristol Myers Squibb@bmsnews

#MEDIA: Announcing @US_FDA has accepted the application for our dual #immunotherapy combination as a potential first-line treatment option for patients with unresectable or metastatic MSI-H or dMMR #colorectalcancer. t.co

Opens with an observation